Search Results for: 19

ROCKVILLE, Md., April 14, 2014 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of the Company’s constipation-predominant irritable bowel syndrome (C-IBS) program. The Company also […]

— Conference Call Today, March 31, 2014, at 10:00 a.m. (EDT) — ROCKVILLE, Md., March 31, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, today reported financial results for the year ended December 31, 2013 and

– Company Focused on Novel Anti-Infective Pipeline for the Prevention and Treatment of Serious Infections and Other Diseases – – Conference Call Scheduled for Monday, March 31, 2014, at 10:00 am EDT – ROCKVILLE, Md., March 25, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates

ROCKVILLE, Md., March 10, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced today that the U.S. Patent & Trademark Office has issued U.S. Patent No. 8,658,627 entitled, Pregnancy Hormone Combination for Treatment of Autoimmune Diseases,

ROCKVILLE, Md., March 5, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the 26th Annual ROTH Conference being held on March 9-12, 2014 at the

ROCKVILLE, Md., Feb. 26, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced today that Founder, Board member and subsidiary CEO and President, Steve H. Kanzer, has resigned from the Company, effective immediately, to return his focus

ROCKVILLE, Md., Jan. 8, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the Biotech Showcase™ 2014 conference next week in San Francisco, as follows: Date: Wednesday, January

ROCKVILLE, Md., Jan. 8, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the 7th Annual OneMedForum San Francisco 2014 conference next week in San Francisco, as follows:

ROCKVILLE, Md., Dec. 17, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, today announced the closing of a previously announced underwritten public offering of 13,225,000 shares of its common stock, including the fully exercised over-allotment option by the

ROCKVILLE, Md., Dec. 13, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, today announced the exercise of the over-allotment option granted to the underwriters to purchase an additional 1,725,000 shares of its common stock, at a price to the